Literature DB >> 12350056

Empiric treatment of minimally abnormal papanicolaou smears with 0.75% metronidazole vaginal gel.

Jeanne M Ferrante1, Dionne Y Mayhew, Seth Goldberg, Laurie Woodard, Cynthia Selleck, Richard G Roetzheim.   

Abstract

BACKGROUND: The purpose of this study was to compare the efficacy of 0.75% metronidazole vaginal gel with no treatment in patients who have had a minimally abnormal Papanicolaou smear.
METHODS: One hundred forty-five patients whose initial Papanicolaou smears were limited by inflammation or benign cellular changes, reactive cellular changes, or atypical squamous cells of undetermined significance that did not favor a neoplastic process were randomized to 5 days of treatment with 0.75% metronidazole vaginal gel or to a control group receiving no treatment. Papanicolaou smears were repeated after 3 to 4 months.
RESULTS: Cytologic findings of the follow-up Papanicolaou smears were normal in 61 of 114 (54%) of patients. Sixty-two percent (n = 37) of the Papanicolaou smears in the control group converted to normal on follow-up, whereas 44% (n = 24) of the Papanicolaou smears in the treatment group converted to normal (P = .07). Only one follow-up Papanicolaou smear worsened to low-grade squamous intraepithelial lesion. In no subgroup was treatment effective.
CONCLUSIONS: Empiric treatment for an asymptomatic, minimally abnormal Papanicolaou smear with 0.75% metronidazole vaginal gel before a repeated cytologic examination did not improve the rate of reversion to normal cytologic findings.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12350056

Source DB:  PubMed          Journal:  J Am Board Fam Pract        ISSN: 0893-8652


  3 in total

1.  Routine Treatment of Cervical Cytological Cell Changes: Diagnostic Standard, Prevention and Routine Treatment of Cervical Cytological Cell Changes - An Assessment of Primary and Secondary Prevention and Routine Treatment Data in the Context of an Anonymous Data Collection from Practicing Gynaecologists; an Academic, Non-Interventional Study.

Authors:  J Huber; B Pötsch; M Gantschacher; M Templ
Journal:  Geburtshilfe Frauenheilkd       Date:  2016-10       Impact factor: 2.915

2.  Efficacy and safety of an adsorbent and anti-oxidative vaginal gel on CIN1 and 2, on high-risk HPV, and on p16/Ki-67: a randomized controlled trial.

Authors:  Attila Louis Major; Vladimír Dvořák; Jana Schwarzová; Aleš Skřivánek; Tomáš Malík; Marek Pluta; Ivanna Mayboroda; Etienne Marc Grandjean
Journal:  Arch Gynecol Obstet       Date:  2020-11-20       Impact factor: 2.344

Review 3.  Human papillomavirus persistence or clearance after infection in reproductive age. What is the status? Review of the literature and new data of a vaginal gel containing silicate dioxide, citric acid, and selenite.

Authors:  Johannes Huber; Anna Mueller; Manuela Sailer; Pedro-Antonio Regidor
Journal:  Womens Health (Lond)       Date:  2021 Jan-Dec
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.